Medicament composition and preparation method thereof

A composition and drug technology, applied in the field of medicine, can solve problems such as easy oxidation, patient pain, poor compliance of muscle agglomeration, difficulty in controlling the particle size of emulsion, etc.

Inactive Publication Date: 2009-07-15
BEIJING CENTURY BIOCOM PHARMA TECH
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The problem in the application of oryzanol is that oryzanol is insoluble in water and easy to oxidize, which makes it difficult to make oryzanol into a stable preparation
However, this invention still does not fundamentally solve the disadvantages of intramuscular injection caused by oil-soluble preparations, which can easily lead to patient pain, muscle agglomeration, and poor compliance.
Chinese patent application 2004100945568 discloses a technical scheme in which oryzanol raw materials are combined with cholesterol and p

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1 Preparation of Cycloartenol Ferulate and 24-Methylene Cycloartenol Ferulate Complex

[0040] 1. Take 1 kg of commercially available oryzanol raw material (purity is 70%), reflux and dissolve with 5 times the mixed solution of ethyl acetate and absolute ethanol with a ratio of 20:1, filter, let stand, filter the precipitated crystals, and dry. The dried crystals (purity about 84%) were reconstituted with 8 times the amount of ethyl acetate, filtered, and allowed to stand, and the precipitated crystals were filtered and dried. The above recrystallization steps were repeated 3-5 times.

[0041] 2. Combine and recover the mother liquor filtered out after recrystallization in step 1 until the volume is 2 times that of the contained solute, then let it stand, filter and dry the precipitated crystals.

[0042] 3. The crystals (purity is about 85-87%) in step 2 are dissolved with 8 times the amount of ethyl acetate under reflux, filtered, left standing, and the preci...

Embodiment 2

[0049] Complex 10mg

[0050] Soy Lecithin 50mg

[0051] Hyodeoxycholic Acid 50mg

[0052] Mannitol 80mg

[0053] Water for injection to 10ml

[0054] Dissolve the complex, soybean lecithin, and hyodeoxycholic acid in 3ml of ethyl acetate, heat to 80°C and stir until fully dissolved. Distilled by evaporation under reduced pressure to obtain an organic phase. Add water for injection in which mannitol has been dissolved to the full amount into the above organic phase, and stir well at 60°C to obtain the composition injection of the present invention. Adjust the pH to 7.3 with sodium hydroxide solution, add 0.05% activated carbon for injection and stir for 30 minutes, after decarburization and filtration, perform fine filtration with a 0.22um microporous filter membrane, and pack into vials.

Embodiment 3

[0056] Complex 40mg

[0057] Soy Lecithin 200mg

[0058] Chenodeoxycholic Acid 300mg

[0059] Glycine 100mg

[0060] Water for injection to 10ml

[0061]Dissolve the complex, chenodeoxycholic acid, and soybean lecithin in 5ml of propylene glycol, heat to 80°C and stir until fully dissolved. Distilled by evaporation under reduced pressure to obtain an organic phase. Add water for injection in which glycine has been dissolved to the full amount into the above organic phase, and stir thoroughly at 70°C to obtain the composition injection of the present invention. Adjust the pH to 9.0 with sodium hydroxide solution, add 0.05% activated carbon for injection and stir for 30 minutes, after decarburization and filtration, perform fine filtration with a 0.22um microporous filter membrane, and pack into vials.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition of cycloartenyl ferulate oryzanolum and a 24-methylene cycloartenyl oryzanolum compound, which comprises the cycloartenyl ferulate oryzanolum, the 24-methylene cycloartenyl oryzanolum compound, phospholipid, bile acid and/or salt of bile acid. The pharmaceutical composition effectively improves the water solubility and the stability of the cycloartenyl ferulate oryzanolum and the 24-methylene cycloartenyl oryzanolum compound and has better grain diameter and stability than the prior product, and further, the invention provides three productforms including injectio, freeze-dried powder and kits of the pharmaceutical composition, and preparation methods thereof.

Description

technical field [0001] The invention relates to a pharmaceutical composition, in particular the invention discloses a pharmaceutical composition for injection and a preparation method thereof, belonging to the field of medicine. Background technique [0002] Oryzanol is a natural mixture composed of cycloartenol-based ferulic acid esters and sterol-based ferulic acid esters. The appearance is white to light yellow crystalline powder, odorless, and has a specific fragrance. Oryzanol mainly exists in rice bran oil and its oil foot. In rice bran oil oryzanol, the content of cycloartenol ferulate is about 70-80%. After long-term research, researchers have found that oryzanol has a variety of physiological functions. Mainly include: lower blood lipid, lower cholesterol absorption, lower serum cholesterol, prevent lipid oxidation and prevent cardiovascular disease. In addition, oryzanol can also alleviate various physical disorders and autonomic nervous disorders in women after ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/575A61K47/24A61P9/00A61P3/06A61P15/12
CPCA61K9/0019A61K31/575A61K9/19A61P3/00A61P3/06A61P5/00A61P9/00A61P15/12A61P25/00
Inventor 郝守祝焦玉焕
Owner BEIJING CENTURY BIOCOM PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap